Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / Fund iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer Blackrock
Entity holding fund iShares VII Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF Ticker CUS1(GBX) LSE
ETF Ticker CUSS(USD) LSE
ETF Ticker SXRG(EUR) F
ETF Ticker CSUSS.MI(EUR) CXE
ETF Ticker CSUSSz(USD) CXE
ETF Ticker CUSS.LS(USD) CXE
ETF Ticker CSUSS(EUR) ETF Plus
ETF Ticker CUS1.L(GBP) LSE
ETF Ticker CUSS.L(GBP) LSE

Holdings detail for CRNX

Stock Name	Crinetics Pharmaceuticals Inc
Ticker	CRNX(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US22663K1079
LEI	549300Q1CNFXK5P31D28

Show aggregate CRNX holdings

News associated with CRNX

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives $68.86 Consensus Price Target from Brokerages: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) has been given a consensus rating of “Moderate Buy” by the nine research firms that are covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price objective […] - 2025-08-19 02:16:54
Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target Cut to $86.00 by Analysts at JMP Securities: Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its target price reduced by JMP Securities from $90.00 to $86.00 in a report published on Monday,Benzinga reports. JMP Securities currently has a market outperform rating on the stock. Several other research firms have also recently weighed in on CRNX. HC Wainwright reaffirmed a “buy” rating and set […] - 2025-08-12 04:47:05
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Victory Capital Management Inc.: Victory Capital Management Inc. lowered its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 10.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 251,331 shares of the company’s stock after selling 30,120 shares during the quarter. Victory Capital Management Inc.’s holdings in […] - 2025-07-25 06:06:53
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of “Moderate Buy” from Brokerages: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) has been given an average recommendation of “Moderate Buy” by the ten brokerages that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month target price […] - 2025-07-22 07:55:07
New York State Common Retirement Fund Sells 17,508 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): New York State Common Retirement Fund lessened its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 11.3% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 137,918 shares of the company’s stock after selling 17,508 shares during the quarter. New York State Common […] - 2025-07-22 07:13:05
Teacher Retirement System of Texas Decreases Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Teacher Retirement System of Texas decreased its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 6.5% in the 1st quarter, Holdings Channel reports. The fund owned 22,442 shares of the company’s stock after selling 1,561 shares during the quarter. Teacher Retirement System of Texas’ holdings in Crinetics Pharmaceuticals were worth $753,000 […] - 2025-07-15 04:24:35
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Consensus Rating of “Moderate Buy” from Brokerages: Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 1 year […] - 2025-07-02 04:30:55
Insider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells $3,141,877.09 in Stock: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) insider Stephen F. Betz sold 97,483 shares of the stock in a transaction dated Thursday, June 12th. The stock was sold at an average price of $32.23, for a total transaction of $3,141,877.09. Following the transaction, the insider now owns 99,713 shares of the company’s stock, valued […] - 2025-06-19 05:10:52
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Acquired by Mackenzie Financial Corp: Mackenzie Financial Corp grew its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 8.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,422 shares of the company’s stock after purchasing an additional 440 shares during the period. Mackenzie Financial Corp’s holdings […] - 2025-06-05 06:18:55
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Rating of “Moderate Buy” from Brokerages: Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) have received an average rating of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company. The average 1 […] - 2025-06-02 02:10:52
State of Wyoming Makes New Investment in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): State of Wyoming purchased a new stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 985 shares of the company’s stock, valued at approximately $50,000. Several other large investors […] - 2025-05-30 05:06:48
Bank of America Corp DE Cuts Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Bank of America Corp DE decreased its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 15.4% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 235,281 shares of the company’s stock after selling 42,792 shares during the period. Bank of America Corp DE’s holdings in Crinetics Pharmaceuticals were worth $12,030,000 […] - 2025-05-23 06:26:56
BNP Paribas Financial Markets Sells 5,683 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): BNP Paribas Financial Markets decreased its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 27.1% in the fourth quarter, Holdings Channel.com reports. The fund owned 15,259 shares of the company’s stock after selling 5,683 shares during the period. BNP Paribas Financial Markets’ holdings in Crinetics Pharmaceuticals were worth $780,000 at the […] - 2025-05-23 04:58:51
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 6,719 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 14.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 53,163 shares of the company’s stock after acquiring an additional 6,719 shares during […] - 2025-05-21 05:40:53
Ameriprise Financial Inc. Has $18.16 Million Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Ameriprise Financial Inc. lifted its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 110.8% during the fourth quarter, Holdings Channel reports. The fund owned 355,174 shares of the company’s stock after buying an additional 186,681 shares during the quarter. Ameriprise Financial Inc.’s holdings in Crinetics Pharmaceuticals were worth $18,159,000 as of […] - 2025-05-16 05:03:19
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Recommendation of “Moderate Buy” by Analysts: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) has earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1 year target […] - 2025-05-08 02:22:53
Envestnet Asset Management Inc. Buys 8,751 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Envestnet Asset Management Inc. boosted its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 16.1% during the 4th quarter, HoldingsChannel reports. The fund owned 63,077 shares of the company’s stock after buying an additional 8,751 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Crinetics Pharmaceuticals were worth $3,225,000 as […] - 2025-04-25 04:24:46
Legal & General Group Plc Buys 12,538 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Legal & General Group Plc lifted its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 16.4% in the 4th quarter, HoldingsChannel.com reports. The fund owned 88,939 shares of the company’s stock after acquiring an additional 12,538 shares during the quarter. Legal & General Group Plc’s holdings in Crinetics Pharmaceuticals were worth $4,547,000 as […] - 2025-04-22 04:47:14
Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Unloaded Rep. Josh Gottheimer: Representative Josh Gottheimer (D-New Jersey) recently sold shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX). In a filing disclosed on April 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Crinetics Pharmaceuticals stock on March 19th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account. Representative Josh […] - 2025-04-14 03:02:59
Corebridge Financial Inc. Buys 1,992 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Corebridge Financial Inc. boosted its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 4.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 43,599 shares of the company’s stock after buying an additional 1,992 shares during the period. Corebridge Financial Inc.’s holdings […] - 2025-04-02 06:46:52
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Vanguard Group Inc.: Vanguard Group Inc. grew its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 44.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 9,089,391 shares of the company’s stock after acquiring an additional 2,801,736 shares during the quarter. Vanguard Group […] - 2025-04-02 05:24:53
16,000 Shares in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Purchased by KLP Kapitalforvaltning AS: KLP Kapitalforvaltning AS bought a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 16,000 shares of the company’s stock, valued at approximately $818,000. A number of other hedge funds have also added to […] - 2025-04-01 05:14:54
Crinetics Pharmaceuticals (NASDAQ:CRNX) Coverage Initiated at Stifel Nicolaus: Analysts at Stifel Nicolaus began coverage on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) in a report released on Tuesday, MarketBeat Ratings reports. The firm set a “buy” rating and a $60.00 price target on the stock. Stifel Nicolaus’ price target would suggest a potential upside of 73.86% from the stock’s previous close. […] - 2025-03-27 04:00:59
Arizona State Retirement System Grows Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Arizona State Retirement System boosted its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 21.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,469 shares of the company’s stock after purchasing an additional 4,168 shares during the […] - 2025-03-14 06:10:48
Assetmark Inc. Purchases 1,014 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Assetmark Inc. raised its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 5.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 18,161 shares of the company’s stock after acquiring an additional 1,014 shares during the quarter. Assetmark Inc.’s holdings in Crinetics Pharmaceuticals […] - 2025-03-12 06:11:03
Keybank National Association OH Has $478,000 Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Keybank National Association OH boosted its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 14.4% in the 4th quarter, HoldingsChannel.com reports. The fund owned 9,352 shares of the company’s stock after purchasing an additional 1,176 shares during the quarter. Keybank National Association OH’s holdings in Crinetics Pharmaceuticals were worth $478,000 at […] - 2025-03-10 05:54:54
Handelsbanken Fonder AB Buys 2,800 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Handelsbanken Fonder AB raised its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 14.7% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 21,800 shares of the company’s stock after purchasing an additional 2,800 shares during the quarter. Handelsbanken Fonder AB’s holdings in Crinetics Pharmaceuticals were worth $1,115,000 at the end […] - 2025-02-28 07:25:04
New York State Common Retirement Fund Purchases 7,735 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): New York State Common Retirement Fund lifted its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 5.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 155,426 shares of the company’s stock after purchasing an additional 7,735 shares during the quarter. New York State Common Retirement Fund’s holdings in Crinetics […] - 2025-02-27 06:51:01
Add Up The Pieces: VBK Could Be Worth $335: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-02-13 13:24:24
TD Cowen Begins Coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX): Analysts at TD Cowen started coverage on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) in a research note issued on Tuesday, MarketBeat.com reports. The firm set a “buy” rating on the stock. CRNX has been the subject of a number of other reports. Wolfe Research started coverage on shares of Crinetics Pharmaceuticals in […] - 2025-02-13 08:26:44

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc CRNX holdings

Date	Number of CRNX Shares Held	Base Market Value of CRNX Shares	Local Market Value of CRNX Shares	Change in CRNX Shares Held	Change in CRNX Base Value	Current Price per CRNX Share Held	Previous Price per CRNX Share Held
2026-01-15 (Thursday)	78,545	USD 4,432,294	USD 4,432,294	12,064	USD 747,917	USD 56.43	USD 55.42
2026-01-14 (Wednesday)	66,481	USD 3,684,377	USD 3,684,377	232	USD 86,394	USD 55.42	USD 54.31
2026-01-13 (Tuesday)	66,249	USD 3,597,983	USD 3,597,983	0	USD -68,899	USD 54.31	USD 55.35
2026-01-12 (Monday)	66,249	USD 3,666,882	USD 3,666,882	0	USD 139,123	USD 55.35	USD 53.25
2026-01-09 (Friday)	66,249	USD 3,527,759	USD 3,527,759	0	USD 662	USD 53.25	USD 53.24
2026-01-08 (Thursday)	66,249	USD 3,527,097	USD 3,527,097	232	USD 5,750	USD 53.24	USD 53.34
2026-01-07 (Wednesday)	66,017	USD 3,521,347	USD 3,521,347	0	USD 487,866	USD 53.34	USD 45.95
2026-01-06 (Tuesday)	66,017	USD 3,033,481	USD 3,033,481	0	USD -147,218	USD 45.95	USD 48.18
2026-01-05 (Monday)	66,017	USD 3,180,699	USD 3,180,699	0	USD 95,725	USD 48.18	USD 46.73
2026-01-02 (Friday)	66,017	USD 3,084,974	USD 3,084,974	0	USD 11,883	USD 46.73	USD 46.55
2025-12-31 (Wednesday)	66,017	USD 3,073,091	USD 3,073,091	0	USD -55,455	USD 46.55	USD 47.39

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of CRNX by Blackrock for IE00B3VWM098

Show aggregate share trades of CRNX

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2026-01-15 BUY 12,064 56.550 53.705 53.990 USD 651,329 39.89
2026-01-14 BUY 232 56.070 53.450 53.712 USD 12,461 39.82
2026-01-08 BUY 232 54.540 52.154 52.393 USD 12,155 39.58
2025-12-23 SELL -232 49.400 48.605 48.684 USD -11,295 39.20 Loss of -2,199 on sale
2025-12-03 SELL -1,160 48.130 44.520 44.881 USD -52,062 38.62 Loss of -7,260 on sale
2025-12-02 BUY 464 46.040 44.595 44.740 USD 20,759 38.59
2025-11-25 BUY 1,636 45.040 43.070 43.267 USD 70,785 38.42
2025-11-24 SELL -675 44.863 43.090 43.267 USD -29,205 38.40 Loss of -3,287 on sale
2025-11-17 SELL -2,475 44.360 41.962 42.202 USD -104,449 38.29 Loss of -9,692 on sale
2025-11-12 SELL -225 43.480 42.050 42.193 USD -9,493 38.22 Loss of -893 on sale
2025-11-06 SELL -225 43.890 42.380 42.531 USD -9,569 38.15 Loss of -986 on sale
2025-11-05 SELL -2,250 43.200 41.410 41.589 USD -93,575 38.12 Loss of -7,796 on sale
2025-11-04 SELL -450 42.780 41.510 41.637 USD -18,737 38.10 Loss of -1,591 on sale
2025-11-03 SELL -450 43.335 42.075 42.201 USD -18,990 38.08 Loss of -1,856 on sale
2025-10-28 BUY 675 42.060 44.100 43.896 USD 29,630 37.97
2025-10-24 SELL -225 40.990 41.520 41.467 USD -9,330 37.92 Loss of -798 on sale
2025-10-15 BUY 1,350 44.150 45.960 45.779 USD 61,802 37.76
2025-10-02 BUY 225 41.510 42.177 42.110 USD 9,475 37.72
2025-09-30 BUY 450 41.650 43.480 43.297 USD 19,484 37.68
2025-08-21 SELL -225 29.400 29.885 29.837 USD -6,713 37.67 Profit of 1,763 on sale
2025-07-31 BUY 675 28.590 29.550 29.454 USD 19,881 37.78
2025-07-28 SELL -225 30.300 31.360 31.254 USD -7,032 37.93 Profit of 1,502 on sale
2025-06-30 SELL -450 28.760 30.351 30.192 USD -13,586 38.79 Profit of 3,868 on sale
2025-06-25 SELL -225 30.410 30.995 30.937 USD -6,961 38.97 Profit of 1,807 on sale
2025-06-20 SELL -450 30.160 30.860 30.790 USD -13,856 39.15 Profit of 3,764 on sale
2025-05-23 BUY 225 29.760 30.545 30.467 USD 6,855 40.46
2025-05-19 SELL -225 30.950 31.920 31.823 USD -7,160 40.80 Profit of 2,020 on sale
2025-05-15 SELL -675 31.210 31.380 31.363 USD -21,170 40.97 Profit of 6,485 on sale
2025-05-12 SELL -225 33.320 33.575 33.550 USD -7,549 41.22 Profit of 1,725 on sale
2025-05-09 SELL -225 30.680 34.340 33.974 USD -7,644 41.31 Profit of 1,651 on sale
2025-04-30 SELL -225 33.390 33.800 33.759 USD -7,596 41.90 Profit of 1,831 on sale
2025-04-24 SELL -450 33.390 33.460 33.453 USD -15,054 42.26 Profit of 3,961 on sale
2025-04-22 BUY 2,707 31.270 31.300 31.297 USD 84,721 42.47
2025-04-17 SELL -216 30.420 30.580 30.564 USD -6,602 42.86 Profit of 2,655 on sale
2025-04-15 SELL -648 29.660 30.460 30.380 USD -19,686 43.15 Profit of 8,272 on sale
2025-04-14 SELL -648 29.780 30.340 30.284 USD -19,624 43.29 Profit of 8,429 on sale
2025-04-09 SELL -864 27.660 27.850 27.831 USD -24,046 43.82 Profit of 13,813 on sale
2025-04-07 SELL -1,512 26.380 27.230 27.145 USD -41,043 44.23 Profit of 25,837 on sale
2025-04-04 SELL -2,170 26.890 28.535 28.370 USD -61,564 44.44 Profit of 34,864 on sale
2025-03-31 BUY 216 33.540 34.545 34.444 USD 7,440 44.90
2025-03-19 SELL -434 34.670 35.000 34.967 USD -15,176 45.99 Profit of 4,783 on sale
2025-03-14 SELL -1,302 34.470 35.630 35.514 USD -46,239 46.47 Profit of 14,261 on sale
2025-03-13 SELL -434 35.040 36.000 35.904 USD -15,582 46.63 Profit of 4,655 on sale
2025-03-12 SELL -7,378 35.400 35.540 35.526 USD -262,111 46.79 Profit of 83,130 on sale
2025-03-07 SELL -434 33.280 34.145 34.059 USD -14,781 47.39 Profit of 5,784 on sale
2025-03-06 SELL -651 34.110 34.455 34.421 USD -22,408 47.59 Profit of 8,573 on sale
2025-03-03 SELL -217 34.140 36.500 36.264 USD -7,869 48.24 Profit of 2,600 on sale
2025-02-28 BUY 10,964 35.780 35.930 35.915 USD 393,772 48.45
2025-02-26 SELL -185 32.550 33.503 33.408 USD -6,180 48.98 Profit of 2,880 on sale
2025-02-25 SELL -555 32.300 34.795 34.545 USD -19,173 49.26 Profit of 8,169 on sale
2025-02-18 BUY 925 35.530 36.477 36.382 USD 33,654 50.50
2025-02-13 BUY 185 35.260 35.850 35.791 USD 6,621 51.41
2025-02-12 BUY 185 35.210 35.220 35.219 USD 6,516 51.74
2025-02-11 BUY 555 34.930 36.660 36.487 USD 20,250 52.09
2025-02-06 BUY 1,665 38.710 39.720 39.619 USD 65,966 53.07
2025-01-27 BUY 185 38.210 40.255 40.051 USD 7,409 56.04
2024-12-30 BUY 920 50.670 51.280 51.219 USD 47,121 57.37
2024-12-06 BUY 736 58.870 59.577 59.506 USD 43,797 57.35
2024-12-05 BUY 184 57.690 58.270 58.212 USD 10,711 57.34
2024-12-04 BUY 920 57.110 58.940 58.757 USD 54,056 57.35
2024-11-29 BUY 920 57.200 57.810 57.749 USD 53,129 57.38
2024-11-27 BUY 736 57.670 58.060 58.021 USD 42,703 57.36
2024-11-26 BUY 184 56.770 56.980 56.959 USD 10,480 57.38
2024-11-25 BUY 5,543 56.090 57.420 57.287 USD 317,542 57.44
2024-11-21 BUY 835 57.030 58.035 57.934 USD 48,375 57.54
2024-11-20 BUY 501 56.070 56.430 56.394 USD 28,253 57.62
2024-11-18 BUY 2,004 53.700 55.050 54.915 USD 110,050 58.02
2024-11-12 BUY 1,328 58.780 60.480 60.310 USD 80,092 57.97
2024-11-08 BUY 830 60.690 60.930 60.906 USD 50,552 57.77
2024-11-07 BUY 2,490 59.810 60.170 60.134 USD 149,734 57.62
2024-11-06 BUY 332 59.160 60.905 60.730 USD 20,163 57.49
2024-10-31 BUY 166 55.960 56.540 56.482 USD 9,376 57.82
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2026-01-15	BUY	12,064	56.550	53.705	53.990	USD 651,329	39.89
2026-01-14	BUY	232	56.070	53.450	53.712	USD 12,461	39.82
2026-01-08	BUY	232	54.540	52.154	52.393	USD 12,155	39.58
2025-12-23	SELL	-232	49.400	48.605	48.684	USD -11,295	39.20 Loss of -2,199 on sale
2025-12-03	SELL	-1,160	48.130	44.520	44.881	USD -52,062	38.62 Loss of -7,260 on sale
2025-12-02	BUY	464	46.040	44.595	44.740	USD 20,759	38.59
2025-11-25	BUY	1,636	45.040	43.070	43.267	USD 70,785	38.42
2025-11-24	SELL	-675	44.863	43.090	43.267	USD -29,205	38.40 Loss of -3,287 on sale
2025-11-17	SELL	-2,475	44.360	41.962	42.202	USD -104,449	38.29 Loss of -9,692 on sale
2025-11-12	SELL	-225	43.480	42.050	42.193	USD -9,493	38.22 Loss of -893 on sale
2025-11-06	SELL	-225	43.890	42.380	42.531	USD -9,569	38.15 Loss of -986 on sale
2025-11-05	SELL	-2,250	43.200	41.410	41.589	USD -93,575	38.12 Loss of -7,796 on sale
2025-11-04	SELL	-450	42.780	41.510	41.637	USD -18,737	38.10 Loss of -1,591 on sale
2025-11-03	SELL	-450	43.335	42.075	42.201	USD -18,990	38.08 Loss of -1,856 on sale
2025-10-28	BUY	675	42.060	44.100	43.896	USD 29,630	37.97
2025-10-24	SELL	-225	40.990	41.520	41.467	USD -9,330	37.92 Loss of -798 on sale
2025-10-15	BUY	1,350	44.150	45.960	45.779	USD 61,802	37.76
2025-10-02	BUY	225	41.510	42.177	42.110	USD 9,475	37.72
2025-09-30	BUY	450	41.650	43.480	43.297	USD 19,484	37.68
2025-08-21	SELL	-225	29.400	29.885	29.837	USD -6,713	37.67 Profit of 1,763 on sale
2025-07-31	BUY	675	28.590	29.550	29.454	USD 19,881	37.78
2025-07-28	SELL	-225	30.300	31.360	31.254	USD -7,032	37.93 Profit of 1,502 on sale
2025-06-30	SELL	-450	28.760	30.351	30.192	USD -13,586	38.79 Profit of 3,868 on sale
2025-06-25	SELL	-225	30.410	30.995	30.937	USD -6,961	38.97 Profit of 1,807 on sale
2025-06-20	SELL	-450	30.160	30.860	30.790	USD -13,856	39.15 Profit of 3,764 on sale
2025-05-23	BUY	225	29.760	30.545	30.467	USD 6,855	40.46
2025-05-19	SELL	-225	30.950	31.920	31.823	USD -7,160	40.80 Profit of 2,020 on sale
2025-05-15	SELL	-675	31.210	31.380	31.363	USD -21,170	40.97 Profit of 6,485 on sale
2025-05-12	SELL	-225	33.320	33.575	33.550	USD -7,549	41.22 Profit of 1,725 on sale
2025-05-09	SELL	-225	30.680	34.340	33.974	USD -7,644	41.31 Profit of 1,651 on sale
2025-04-30	SELL	-225	33.390	33.800	33.759	USD -7,596	41.90 Profit of 1,831 on sale
2025-04-24	SELL	-450	33.390	33.460	33.453	USD -15,054	42.26 Profit of 3,961 on sale
2025-04-22	BUY	2,707	31.270	31.300	31.297	USD 84,721	42.47
2025-04-17	SELL	-216	30.420	30.580	30.564	USD -6,602	42.86 Profit of 2,655 on sale
2025-04-15	SELL	-648	29.660	30.460	30.380	USD -19,686	43.15 Profit of 8,272 on sale
2025-04-14	SELL	-648	29.780	30.340	30.284	USD -19,624	43.29 Profit of 8,429 on sale
2025-04-09	SELL	-864	27.660	27.850	27.831	USD -24,046	43.82 Profit of 13,813 on sale
2025-04-07	SELL	-1,512	26.380	27.230	27.145	USD -41,043	44.23 Profit of 25,837 on sale
2025-04-04	SELL	-2,170	26.890	28.535	28.370	USD -61,564	44.44 Profit of 34,864 on sale
2025-03-31	BUY	216	33.540	34.545	34.444	USD 7,440	44.90
2025-03-19	SELL	-434	34.670	35.000	34.967	USD -15,176	45.99 Profit of 4,783 on sale
2025-03-14	SELL	-1,302	34.470	35.630	35.514	USD -46,239	46.47 Profit of 14,261 on sale
2025-03-13	SELL	-434	35.040	36.000	35.904	USD -15,582	46.63 Profit of 4,655 on sale
2025-03-12	SELL	-7,378	35.400	35.540	35.526	USD -262,111	46.79 Profit of 83,130 on sale
2025-03-07	SELL	-434	33.280	34.145	34.059	USD -14,781	47.39 Profit of 5,784 on sale
2025-03-06	SELL	-651	34.110	34.455	34.421	USD -22,408	47.59 Profit of 8,573 on sale
2025-03-03	SELL	-217	34.140	36.500	36.264	USD -7,869	48.24 Profit of 2,600 on sale
2025-02-28	BUY	10,964	35.780	35.930	35.915	USD 393,772	48.45
2025-02-26	SELL	-185	32.550	33.503	33.408	USD -6,180	48.98 Profit of 2,880 on sale
2025-02-25	SELL	-555	32.300	34.795	34.545	USD -19,173	49.26 Profit of 8,169 on sale
2025-02-18	BUY	925	35.530	36.477	36.382	USD 33,654	50.50
2025-02-13	BUY	185	35.260	35.850	35.791	USD 6,621	51.41
2025-02-12	BUY	185	35.210	35.220	35.219	USD 6,516	51.74
2025-02-11	BUY	555	34.930	36.660	36.487	USD 20,250	52.09
2025-02-06	BUY	1,665	38.710	39.720	39.619	USD 65,966	53.07
2025-01-27	BUY	185	38.210	40.255	40.051	USD 7,409	56.04
2024-12-30	BUY	920	50.670	51.280	51.219	USD 47,121	57.37
2024-12-06	BUY	736	58.870	59.577	59.506	USD 43,797	57.35
2024-12-05	BUY	184	57.690	58.270	58.212	USD 10,711	57.34
2024-12-04	BUY	920	57.110	58.940	58.757	USD 54,056	57.35
2024-11-29	BUY	920	57.200	57.810	57.749	USD 53,129	57.38
2024-11-27	BUY	736	57.670	58.060	58.021	USD 42,703	57.36
2024-11-26	BUY	184	56.770	56.980	56.959	USD 10,480	57.38
2024-11-25	BUY	5,543	56.090	57.420	57.287	USD 317,542	57.44
2024-11-21	BUY	835	57.030	58.035	57.934	USD 48,375	57.54
2024-11-20	BUY	501	56.070	56.430	56.394	USD 28,253	57.62
2024-11-18	BUY	2,004	53.700	55.050	54.915	USD 110,050	58.02
2024-11-12	BUY	1,328	58.780	60.480	60.310	USD 80,092	57.97
2024-11-08	BUY	830	60.690	60.930	60.906	USD 50,552	57.77
2024-11-07	BUY	2,490	59.810	60.170	60.134	USD 149,734	57.62
2024-11-06	BUY	332	59.160	60.905	60.730	USD 20,163	57.49
2024-10-31	BUY	166	55.960	56.540	56.482	USD 9,376	57.82

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of CRNX

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	291,811	10	422,190	69.1%
2025-09-18	255,311	4,887	441,317	57.9%
2025-09-17	188,956	0	259,138	72.9%
2025-09-16	203,554	46	341,724	59.6%
2025-09-15	274,635	30	448,716	61.2%
2025-09-12	212,918	4	332,544	64.0%
2025-09-11	387,813	4,439	687,673	56.4%
2025-09-10	271,583	180	472,484	57.5%
2025-09-09	435,551	10,514	645,587	67.5%
2025-09-08	321,931	100	446,007	72.2%
2025-09-05	341,734	5,833	547,129	62.5%
2025-09-04	381,128	0	505,163	75.4%
2025-09-03	545,896	3,603	690,216	79.1%
2025-09-02	320,458	1,530	581,108	55.1%
2025-08-29	302,502	0	582,657	51.9%
2025-08-28	200,718	0	302,611	66.3%
2025-08-27	102,469	343	177,212	57.8%
2025-08-26	112,474	0	194,567	57.8%
2025-08-25	165,204	0	263,113	62.8%
2025-08-22	187,758	3,090	538,677	34.9%
2025-08-21	185,854	1,565	714,284	26.0%
2025-08-20	88,347	12	180,947	48.8%
2025-08-19	127,062	1,989	256,813	49.5%
2025-08-18	98,462	0	154,915	63.6%
2025-08-15	272,245	2,909	364,113	74.8%
2025-08-14	195,415	5,120	386,307	50.6%
2025-08-13	180,925	108	441,798	41.0%
2025-08-12	123,251	0	304,481	40.5%
2025-08-11	254,714	1,686	471,534	54.0%
2025-08-08	427,524	71	845,094	50.6%
2025-08-07	232,990	0	429,931	54.2%
2025-08-06	245,049	453	455,360	53.8%
2025-08-05	201,437	1,908	582,449	34.6%
2025-08-04	105,804	12	271,833	38.9%
2025-08-01	189,908	631	307,789	61.7%
2025-07-31	156,522	0	272,309	57.5%
2025-07-30	177,608	0	284,862	62.3%
2025-07-29	186,650	1,295	330,974	56.4%
2025-07-28	135,934	800	165,427	82.2%
2025-07-25	170,240	173	313,564	54.3%
2025-07-24	100,554	82	184,823	54.4%
2025-07-23	119,806	200	158,505	75.6%
2025-07-22	102,666	226	190,447	53.9%
2025-07-21	154,005	0	288,631	53.4%
2025-07-18	184,879	1,777	371,360	49.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE